Measuring phosphorylated tau‑217 (pTau217) in donated blood plasma
Official title: Detection of Elevated Plasma pTau217 in Donated Human Blood Samples: Implications for Blood Transfusion Safety
Run by The University of Texas Health Science Center, Houston · NCT07157839 · Data updated 2026-11-12
This project will test donated blood plasma to see if some units contain high levels of phosphorylated tau‑217, a marker linked to Alzheimer's disease.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | August 28, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | November 1, 2026 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07157839 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal samples are plasma units donated through blood banks, supplemented by control plasma from people with clinically diagnosed Alzheimer's disease and healthy control participants.
✕Probably not a fit
Because this is a lab-based observational analysis of stored plasma samples, individual donors or recipients are unlikely to receive direct clinical benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, laboratory-based study will measure pTau217 concentrations in about 250 donated plasma samples collected through a blood bank, including purchased samples from clinically diagnosed Alzheimer's patients and healthy controls. Measurements will use a nanoneedle biosensor or equivalent immunoassays and will compare pTau217 concentrations to total tau. The design is cross-sectional and prospective, with aliquots retained for potential further analysis. The main goals are to determine how often donated plasma shows elevated pTau217 and to generate preliminary data relevant to transfusion safety.
Why it matters
Potential benefit: If results show some donated plasma has high pTau217, they could inform screening practices to reduce potential Alzheimer's-related risks from transfusions.
How similar studies have gone: Prior research has shown blood pTau217 is a sensitive and specific biomarker for Alzheimer's disease, but applying pTau217 measurement to general blood donations and transfusion safety is a novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The plasma sample from donators. Exclusion Criteria: * None.
Where it's running
-
University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Zhongcong Xie, M.D., Ph.D. — The University of Texas Health Science Center, Houston
- Study coordinator: Zhongcong Xie, M.D., Ph.D.
- Email: Zhongcong.Xie@uth.tmc.edu
- Phone: 17135006207
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using deep rTMS to improve memory in Alzheimer's Disease
This study is testing if a new brain treatment called deep rTMS can help improve memory in people with mild to moderate Alzheimer's Disease.
-
Home-based brain stimulation plus online chair yoga for chronic knee pain in people with Alzheimer's disease
This project will test whether combining home-based low-intensity brain stimulation (tDCS) with online chair yoga can reduce chronic knee pain in older adults with Alzheimer's disease and related dementias.
-
Using brain stimulation to improve memory and motivation in older adults
This study is testing if a type of brain stimulation can help improve memory and motivation in older adults, including those showing early signs of Alzheimer's disease.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Carotid artery wall viscosity and memory problems in older adults
This project will test whether the viscous behavior of the carotid artery wall is linked to memory problems in people over 70 with memory complaints, Alzheimer's disease, or vascular dementia.
-
DUVAX: a first-in-human vaccine for amyloid and tau targets in adults 40-65
A first-in-human vaccine called DUVAX is tested in healthy adults to see if it's safe and whether it triggers an immune response against Alzheimer’s-related proteins.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.